No summary available
No summary available
No summary available
Drs. Catherine Smith, PharmD, BCPS, BCPP, and Kristin Helmboldt, PharmD, BCPP, share how systematic thinking, shared decision-making, and the acknowledgement of uncertainty can assist with clinical decision-making in evidence gaps.
For 15 years, the AAPP Foundation has helped advance research that strengthens psychiatric pharmacy and supports better-informed practice. In 2026, your gift can support the quest to improve best practices and outcomes. Contributions made by December 31 can be matched dollar for dollar, up to $30,000. Together, we can turn $30,000 in donations into as much as $60,000 in support for the future of the profession. Help move promising ideas forward.
A $50 gift can become $100. A $250 gift can become $500. A $1,000 gift can become $2,000. Through December 31, 2026, generous donors are providing up to $30,000 in matching funds for gifts to the AAPP Foundation. Every contribution brings us closer to our $30,000 fundraising goal and the opportunity to generate up to $60,000 for research, innovation, and workforce growth and development. Give today! #MatchingGift #DoubleYourGift #AAPPFoundation #PsychiatricPharmacy #Generosity
2026 marks 15 years of supporting research, encouraging innovation, and strengthening the psychiatric pharmacy workforce. We are laying the foundation for the next 15 years, and your generosity today can help create lasting momentum for the profession tomorrow. Help us reach $30,000 and unlock up to $60,000 in impact. #15YearsOfImpact #AAPPFoundation #PsychiatricPharmacy #GiveBack #MatchingFunds
This year, the AAPP Foundation celebrates 15 years of advancing research, innovation, and workforce growth and development in psychiatric pharmacy! Thanks to two groups of generous donors, every contribution through Dec. 31, 2026, can be matched dollar-for-dollar, up to $30,000 for a total impact of $60,000! Join us in building toward the next 15 years. Make your gift today and double your impact. #AAPPFoundation #PsychiatricPharmacy #MatchingGift #DoubleYourImpact #Philanthropy
AAPP’s harm reduction policy brief outlines recommended policy reforms that prioritize public health, person-centered care, and the perspectives of people who use drugs while reducing barriers that limit engagement with care.
This webinar will review the key design and primary and secondary outcomes from NIDA Clinical Trials Network Study 0080. This landmark study randomized 140 pregnant adults with moderate-severe OUD across multiple collaborative care addiction and OB/GYN treatment programs. Participants were randomized to either extended-release buprenorphine or sublingual buprenorphine. Study treatment was provided through delivery and for 12 months post-partum.
AAPP’s newest policy calls for public policies that expand access to evidence-based harm reduction services, including overdose prevention resources, syringe services, and other measures that reduce the health risks associated with substance use. It emphasizes that harm reduction is a critical public health strategy that saves lives, improves engagement in care, and should be supported through legislation, funding, and the removal of barriers to access.
Brexpiprazole, when used as maintenance treatment for adolescents with schizophrenia, has a safety profile generally consistent with that observed in adult patients.
A new CDC study, Morbidity and Mortality Weekly Report (MMWR): Buprenorphine Dispensed by Pharmacies and Administered in Emergency Departments in Urban and Rural Areas — United States, 2019–2025 examines access to buprenorphine in urban and rural communities from 2019–2025. The findings show progress in expanding access to treatment, while also identifying continued opportunities to help more people start and stay in care including strengthening pharmacy availability.
This document highlights 4 empirically supported treatment suggestions for SUD/PSU in youth. Despite the magnitude of the problem, there is a paucity of safe and effective treatments for adolescents and young adults with SUD/PSU, suggesting the urgent need for additional research.
No summary available
In this study, GLP-1 RA initiation was associated with lower mortality and cardiovascular events compared to SGLT2 inhibitor initiation, with greater absolute reductions in SMI.
This paper provides an overview of recent advances in the use of psychedelics as medicine, along with research needs, safety considerations, and the system capacity and infrastructure needed to support their use.
These results suggest that adolescent and past-year alcohol use may differentially impact habitual responding and attentional bias towards non-drug reward cues.
Most of the sample did not engage with hospital or substance use treatment services after a nonfatal overdose. Negative prior experiences and fear of negative consequences were major barriers in this sample.
This cross-sectional study found divergent age- and sex-specific patterns from 2021 through 2024.
Among adolescents who vaped nicotine and were undergoing substance use disorder treatment, this study observed an abrupt increase in cotinine concentrations from 2023 to 2025.
This pilot trial indicates that the ADS Program is feasible, safe, and potentially effective in supporting self-management of SAC.
THC use disorders seemed to be associated with an increased risk of spirometry-defined SAD and lower small airways spirometric value in this population-based cohort, highlighting the need for screening of THC in patients investigated for SAD.
This study sought to characterize the biosignatures of craving through the measurement of HRV using a combination of ECG monitoring and EMA in individuals in the first year of a current AUD recovery attempt.
These findings confirm previous results among non–treatment seekers with less severe AUD and suggest that continued development of semaglutide for AUD is warranted.
Learn how having psychiatric pharmacists on the team impact child and adolescent psychiatric care.